Key result
Short-term antipsychotic use linked to DVT in two reported cases.
Why the study?
Does antipsychotic drug use increase the risk of deep vein thrombosis in patients without major risk factors?
Case Report (n=2)
Does antipsychotic drug use increase the risk of deep vein thrombosis in patients without major risk factors?
Short-term use of antipsychotic agents, particularly low-potency ones, may be a risk factor for the development of deep vein thrombosis.
Answers are grounded in this paper and cite their sources.
Short-term antipsychotics may signal DVT risk in low-risk women; hypothesis-generating case reports leave causal confirmation open.
Deep vein thrombosis (DVT) and subsequent pulmonary embolism as an adverse effect of antipsychotic medications has come under attention. We report two cases of DVT associated with the use of antipsychotic agents. Deep venous thrombosis is partial or complete obstruction of leg veins by thrombus causing edema, distention, and pain in one leg. The most critical complication of DVT is pulmonary thromboembolism. Approximately 50% of untreated DVT is said to cause pulmonary thromboembolism, the direct mortality rate of which is 10%.1 Annually, approximately 500 000–600 000 cases of pulmonary thromboembolism occur in the USA.1 In Japan, the cases are on the rise.2 Prolonged immobility, trauma, surgery that can trigger blood clots, pregnancy, and coagulopathy are known risk factors for DVT. However, a strong relationship between antipsychotic drugs and the occurrence of DVT has been reported mainly in Europe.3-5 In Japan, one reported case of chronic thromboembolic pulmonary hypertension associated with antipsychotic use exists.6 In this paper we present two cases of DVT that occurred during treatment with antipsychotic drugs. The first patient was a 57-year-old woman whose chief complaint was dyspnea. She had been on bromperidol 3 mg/day to treat schizophrenia for 2 years. During a suicide attempt, the patient ingested 70 mg bromperidol and 14 mg flunitrazepam at one time. Two hours later in the emergency room, the patient underwent gastrolavage before being admitted to the general practice department. Seven hours later, the patient presented with sudden dyspnea and tachypnea. There was no history of prior surgery, trauma, or heart failure. The patient was not obese (body mass index (BMI): 25 kg/m2), and had been ambulatory before admission. Laboratory data revealed elevated C-reactive protein. Her coagulation profile was normal. Arterial blood gas analysis showed hypoxia. Pulmonary blood flow scintigram showed multiple defects in the right upper and middle lobes. Lower limb venography showed a thrombus in the right tibial vein, but both femoral veins were patent. Heparin with urokinase was given intravenously, which was then followed by warfarin. The patient's symptoms and arterial gas level improved. On day 16 of admission, the patient was transferred to the psychiatric department for the treatment of schizophrenia. The second patient was a 75-year-old woman who complained of left leg edema. The patient had been treated for major depression using occasional antidepressant medication for 1 year. The patient was admitted to a psychiatric ward due to the exacerbation of her depressive symptoms and the emergence of delirium. Chlorpromazine at 10 mg/day was started for her symptoms. Three days later redness and edema appeared in her left leg. The patient did not have any previous history of surgery, trauma, heart failure, or coagulopathy. Before admission, her physical activity was normal and the patient was not obese (BMI: 17 kg/m2). Slight anemia and an elevated C-reactive protein level were found but liver and kidney function tests results were normal. Abnormal results were found in the coagulation profile, but hematostasis/thrombosis specialists later considered these findings as an activation of fibrinolysis due to a massive thrombus. Doppler ultrasonography showed a massive thrombus that completely occluded the lumen from the left common iliac vein to the femoral vein. Short-term heparin administration in conjunction with continuous warfarin treatment helped to stabilize the patient. A follow-up Doppler study showed that the thrombus in the left femoral vein had shrunk and there was recanalization of blood flow. Although antipsychotic agents have been widely used both in psychiatric and general medical practice, their association with the occurrence of DVT was only recently discovered. Zornberg and Jick proved epidemiologically the direct relationship between antipsychotic drug use and the occurrence of DVT.3 They did not find a dose–response effect between antipsychotic agents and DVT. However, they demonstrated that low-potency agents such as chlorpromazine and thioridazine have a stronger correlation with DVT than high-potency agents such as haloperidol (odds ratio (OR): 24.1 vs 3.3). The risk power of antipsychotics, especially that of low-potency agents is high when we consider the risk of other factors such as a past history of DVT (OR: 9.4), malignancy (OR: 4.3), and previous immobilization (OR: 1.9).7 No association was found between antidepressant use alone and subsequent risk of DVT.3 The molecular mechanism of this relationship has yet to be fully elucidated. Because many factors can affect the incidence of DVT, we cannot determine the direct correlation between antipsychotic drugs and DVT in these two cases. However, both patients had no major risk factors for DVT. In addition, the occurrences of the DVT coincided with the administration of antipsychotics. Therefore, it is strongly suggested that antipsychotic drugs played a role in the etiology of DVT in these cases. In case 1, bromperidol, a high-potency–lower risk agent, was used for 2 years before the embolism occurred, although ingestion of the large dose may have triggered the incident. In contrast, massive thrombosis developed only 3 days after initiation of chlorpromazine, a low-potency–higher risk agent, in case 2. The difference in the duration of antipsychotic use between case 1 and case 2 may reflect the difference of drug potency, that is, the risk power of the drug used in each case. In Japan, Chino et al. reported a case of chronic thromboembolic pulmonary hypertension, which was possibly associated with antipsychotic intake.6 The patient had taken an antipsychotic drug for decades, which suggested the possibility of long-term antipsychotic intake and its relationship with DVT and pulmonary thromboembolism. However, the present cases, especially the second case, show that short-term administration of an antipsychotic drug could cause DVT. Zornberg and Jick also suggested that the risk was highest during the first 3 months of antipsychotic use.3 Therefore, we suggest that short-term use of antipsychotic agents should be included as a risk for development of DVT.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2004) conducted a case report in Deep vein thrombosis (n=2). Antipsychotic drugs (bromperidol, chlorpromazine) was evaluated on Deep vein thrombosis. Two cases of deep vein thrombosis occurred in female patients following the administration of antipsychotic drugs, suggesting a potential association even with short-term use.
Synapse has enriched 10 related papers. Consider them for comparative context: